ALB and neoplasm: Lu and colleagues designed an innovative β-glucuronidase-responsible albumin-binding prodrug, SN38-glu-Mal, to selectively deliver SN38 to tumor sites for maximum efficacy (Figure 4B) (Huang et al., 2021).